You are not logged in
Login
Create Account
Meetings
Help
Contact Us
Visit our Twitter
Visit our LinkedIn
HER2 testing: The evolving role of immunohistochemistry - best practices and interpretation of results in lung and ovarian cancer - Pre-Meeting Survey - 11-03-2025
If you wish to view the details for the meeting, then please click the button.
Back to the Meeting Details
Name
*
Email Address
*
What is the primary role of HER2 immunohistochemistry (IHC) in lung and ovarian cancer?
*
To determine the presence of HER2 mutations in the tumour
To evaluate HER2 protein expression levels and guide treatment decisions
To predict the response to immune checkpoint inhibitors
To predict response to chemotherapy
Which of the following statements is correct regarding HER2 testing in lung and ovarian cancer?
*
IHC is sufficient for detecting all HER2 alterations, including mutations
IHC is primarily used to assess HER2 protein expression, while additional tests like in situ hybridization (ISH) or next-generation sequencing (NGS) may be needed for gene amplification or mutation detection
HER2 testing is only relevant in breast and gastric cancer, not in lung or ovarian cancer
IHC scoring is standardized across all tumour types
When performing HER2 IHC on a lung or ovarian cancer biopsy, what is the recommended scoring system used to evaluate HER2 expression?
*
A similar 0 to 3+ scoring system used in breast and gastric cancer, though interpretation may differ in lung and ovarian cancer
A binary system (positive or negative)
A continuous numerical scale from 1 to 100
An H-score
On a scale of 1 to 5, how do you rate your knowledge (with 5 as extremely knowledgeable) on best practices in HER2 immunohistochemistry testing?
*
1
2
3
4
5
On a scale of 1 to 5, how familiar are you (with 5 as extremely familiar) with optimal immunohistochemistry testing and scoring of staining for HER2 expression?
*
1
2
3
4
5
On a scale of 1 to 5, how confident (with 5 as extremely confident) are you in recognizing the appropriate placement of therapies targeting HER2 alterations across the patient journey in ovarian and/or lung cancer?
*
1
2
3
4
5
For treating physicians, on average how many patients with lung and/or ovarian do you see each month?
*
0-5
6-20
21-40
41-60
>60
For pathologists, where do you conduct your HER2 immunohistochemistry testing?
In-house laboratory/facility
Third-party laboratory
Not performed at my institute
Do you have any questions you would like to ask the faculty?
Submit your patient case study for the faculty via email to selina.gill@cor2ed.com
Choose File
No file chosen
Delete uploaded file
Submit
COR2ED develops and implements high quality Independent Medical Education programmes to help improve the health of patients globally.
Bodenackerstrasse 17
4103 Bottmingen
Switzerland
Products
Webinars
Meetings
On Demand
SUPPORT
HELP
CONTACT US
Disclaimer: The material and content contained in the website engage.cor2ed.com is for healthcare professionals only. Although every effort is made to ensure that the material within this website is accurate and timely, it is provided for informational and educational purposes only. The information provided is not intended as a substitute for medical professional help, advice, diagnosis or treatment and may not be applicable to every case or country.
© Copyright 2021 | All Rights Reserved
Cookies
Privacy Policy
map-marker
sign-in
user-plus
linkedin
facebook
pinterest
youtube
rss
twitter
instagram
facebook-blank
rss-blank
linkedin-blank
pinterest
youtube
twitter
instagram
We use cookies in order to give you the best possible experience on our website. By continuing to use this site, you agree to our use of cookies.
Accept
View Cookie Policy
